Zou Zhi-Qiang, Du Yi-Ying, Sui Gang, Xu Shi-Ning
Department of Thoracic Surgery, Jinan Military General Hospital, Jinan, Shandong, China E-mail :
Asian Pac J Cancer Prev. 2015;16(8):3189-94. doi: 10.7314/apjcp.2015.16.8.3189.
To explore the expression of TS, RRM, ERCC1, TUBB3 and STMN1 genes in the tissues of patients with non-small cell lung cancer (NSCLC) and its significance in guiding the postoperative adjuvant chemotherapy.
Real time polymerase chain reaction (PCR) was applied to detect the expression of TS, RRM, ERCC1, TUBB3 and STMN1 genes in the tissues of NSCLC patients so as to analyze the relationship between the expression of each gene and the clinical characteristics and to guide the postoperative individualized chemotherapy according to the detection results of NSCLC patients.
Expression of TS gene was evidently higher in patients with adenocarcinoma than those with non-adenocarcinoma (P=0.013) and so was the expression of ERCC1 (P=0.003). The expression of TUBB3 gene was obviously higher in NSCLC patients in phases I/II and IV than those in phase III (P1=0.021; P2=0.004), and it was also markedly higher in patients without lymph node metastasis than those with (P=0.008). The expression of STMN1 gene was apparently higher in patients in phase I/II than those in phase IV (P=0.002). There was no significant difference between the rest gene expression and the clinical characteristics of NSCLC patients (P>0.05). Additionally, the disease- free survival (DFS) was significantly longer in patients receiving gene detections than those without (P=0.021).
The selection of chemotherapeutic protocols based singly on patients' clinical characteristics has certain blindness. However, the detection of tumor-susceptible genes can guide the postoperative adjuvant chemotherapy and prolong the DFS of NSCLC patients.
探讨胸苷酸合成酶(TS)、核糖核苷酸还原酶亚基M1(RRM)、切除修复交叉互补基因1(ERCC1)、β-微管蛋白Ⅲ(TUBB3)和生存素1(STMN1)基因在非小细胞肺癌(NSCLC)患者组织中的表达及其在指导术后辅助化疗中的意义。
应用实时聚合酶链反应(PCR)检测NSCLC患者组织中TS、RRM、ERCC1、TUBB3和STMN1基因的表达,分析各基因表达与临床特征的关系,并根据NSCLC患者的检测结果指导术后个体化化疗。
腺癌患者TS基因表达明显高于非腺癌患者(P = 0.013),ERCC1基因表达情况亦如此(P = 0.003)。I/II期和IV期NSCLC患者TUBB3基因表达明显高于III期患者(P1 = 0.021;P2 = 0.004),无淋巴结转移患者的TUBB3基因表达也明显高于有淋巴结转移者(P = 0.008)。I/II期患者STMN1基因表达明显高于IV期患者(P = 0.002)。其余基因表达与NSCLC患者临床特征之间无显著差异(P > 0.05)。此外,接受基因检测的患者无病生存期(DFS)明显长于未接受检测的患者(P = 0.021)。
单纯根据患者临床特征选择化疗方案具有一定盲目性。然而,检测肿瘤易感基因可指导术后辅助化疗并延长NSCLC患者的DFS。